Sarepta Therapeutics’ (SRPT) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Thursday morning,Benzinga reports. The firm currently has a $202.00 target price on the biotechnology company’s stock. A number of other analysts have also issued reports on SRPT. Deutsche Bank Aktiengesellschaft assumed coverage on […]
Needham & Company LLC restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Thursday morning,Benzinga reports. The firm currently has a $202.00 target price on the biotechnology company’s stock. A number of other analysts have also issued reports on SRPT. Deutsche Bank Aktiengesellschaft assumed coverage on […]
